Gliadel_Wafer: profile and news

MGI Pharma Misses Targets  Feb 8, 2006
...expects revenue to be in the range of $370 million to $385 million, including Aloxi injection sales of $285 million to $300 million, and Gliadel Wafer sales of ... - TheStreet.com

MGI Pharma Misses Targets  Feb 8, 2006
...expects revenue to be in the range of $370 million to $385 million, including Aloxi injection sales of $285 million to $300 million, and Gliadel Wafer sales of ... - TheStreet.com

UPDATE 1-MGI Pharma 2006 revenue outlook below expectations  Jan 10, 2006
The company said it expects to recognize about $8.5 million in fourth-quarter 2005 sales of Gliadel Wafer, a brain cancer treatment, and $34 million for the ... - Reuters

MGI Sees 2006 Sales Below Wall Street View  Jan 10, 2006
Sales of the Gliadel wafer, an implant for brain tumor patients, hit $34 million for the year, about $8.5 million of that since MGI acquired the product in ... - MSN Money

MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection ...  Jan 10, 2006
Wafer. Total sales of Gliadel Wafer were approximately $34 million (unaudited) in 2005, a 22% increase over 2004 sales. -- Oncology ... - Genetic Engineering News,

MGI Pharma provides '06 sales guidance  Jan 10, 2006
Sales of Gliadel Wafer, a brain tumor treatment acquired in MGI Pharma's purchase of Guilford Pharmaceuticals in October, rose 22 percent to $34 million in 2005 ... - Twin Cities Business Journal,

GSW Worldwide to Lead SaforisTM Launch Campaign for MGI PHARMA ...  Nov 14, 2005
MGI PHARMA markets Aloxi ® (palonosetron hydrochloride) injection and Gliadel ® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals  Oct 3, 2005
MGI PHARMA expects that Gliadel Wafer will be complementary with the Company's existing oncology franchise and immediately additive to MGI PHARMA's revenues. ... - Genetic Engineering News,

MGI Pharma completes acquisition of Guilford Pharmaceuticals  Oct 4, 2005
...late-stage acute care development pipeline by adding Aquavan Injection, a complementary product to Aloxi injection for PONV, and adds Gliadel Wafer to our ... - Pharmaceutical Business Review

Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA ...  Sep 29, 2005
Presently, Guilford markets two commercial products, Gliadel® wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and Aggrastat ... - Yahoo! News (press release)

Experts guide brain cancer vaccine development  Sep 27, 2005
...developed new clinical treatments for brain tumors including the local delivery of chemotherapeutic agents in biodegradable polymers, Gliadel wafer, for which ... - myDNA.com,

NeoPharm gets FDA OK for analysis  Aug 24, 2005
...company to include an interim analysis of data to see how the treatment cintredekin besudotox compares with patients receiving the Gliadel wafer, an implanted ... - BusinessWeek

MGI PHARMA and Guilford Pharmaceuticals Announce Expiration of the ...  Sep 1, 2005
For additional prescribing information about Gliadel wafer and Aggrastat injection please see http://www.guilfordpharm.com. MGI PHARMA, INC. ... - Genetic Engineering News,

Gloucester Pharmaceuticals Strengthens Management Team in Key ...  Aug 25, 2005
...to Gloucester over ten years of commercial oncology experience with a variety of products including Taxotere(R), Velcade(R), Oncaspar(R), Gliadel Wafer(R) and ... - PharmaLive.com (press release),

Health Stocks in Motion  Aug 24, 2005
...the second quarter of 2006, will be conducted after notification of 160 deaths to demonstrate potential superiority of cintredekin besodotox over Gliadel wafer ... - TheStreet.com

Orphan drugs moving ahead  Aug 28, 2005
20 companies have developed about 85 orphan drugs, at least 16 of which have made it to market, such as Guilford Pharmaceuticals' Gliadel Wafer treatment for ... - Baltimore Sun,

Brain cancer in its sights  Aug 14, 2005
Two hundred patients will receive one treatment of IL13-PE38QQR, while the remainder will be treated with a Gliadel wafer, an anti-cancer drug that is ... - Los Angeles Times,

MGI Pharma to acquire Guilford Pharmaceuticals  Jul 22, 2005
In particular, MGI will gain access to Guilford's Gliadel Wafer brain cancer treatment and the experimental Aquavan sedation drug for use during procedures ... - Pharmaceutical Business Review

MGI PHARMA to Acquire Guilford Pharmaceuticals  Jul 21, 2005
Second, the increased development and commercialization scale will allow maximization of the market potential of Aquavan injection and Gliadel wafer. ... - Business Wire (press release)

Guilford Pharmaceuticals to Announce Second Quarter 2005 Financial ...  Aug 2, 2005
Presently, Guilford markets two commercial products, GLIADEL® Wafer, for the treatment of brain cancer, and AGGRASTAT® Injection, a glycoprotein GP IIb/IIIa ... - Yahoo News (press release)

City biotech sold to MGI Pharma for $177 million  Jul 22, 2005
Lexington, Mass. - along with a marketed brain cancer treatment, called the Gliadel Wafer, to add to its oncology portfolio. The ... - Baltimore Sun

MGI to Buy Guilford for $177.5 Million  Jul 21, 2005
..."The increased development and commercialization scale will allow maximization of the market potential of Aquavan injection and Gliadel wafer," said Guilford ... - Forbes

NeoPharm shares jump on new 'buy' rating  Jul 15, 2005
...besudotox after surgery survive at least 50 percent longer compared with those treated with Maryland-based Guilford Pharmaceuticals Inc.’s Gliadel wafer. ... - Crain's Chicago Business

RPT-UPDATE 1-MGI Pharma to acquire Guilford Pharmaceuticals  Jul 21, 2005
Guilford's key products include the Gliadel Wafer brain cancer treatment and the Aquavan sedation drug for use during procedures such as colonoscopy. ... - Reuters <**results**>

Interim CEO on Neopharm's short list for permanent post  Jun 30, 2005
On the current existing treatment known as Gliadel Wafer, median survival is 28 weeks, which means Neopharm's IL-13 has to improve median survival to 42 weeks. ... - Chicago Tribune

NeoPharm gets some good news  Jun 29, 2005
...a 50 percent increase in survival for brain cancer patients, compared to treatment with the US Food and Drug Administration-approved Gliadel Wafer of Maryland ... - Chicago Daily Herald

NeoPharm clears hurdle in brain canc  Jun 27, 2005
...cancer treated with its cintrediken besudotox after surgery survive at least 50 percent longer compared with those treated with the Gliadel wafer, the current ... - Crain's Chicago Business,

NeoPharm clears hurdle in brain canc  13 Sep 2002
...cancer treated with its cintrediken besudotox after surgery survive at least 50 percent longer compared with those treated with the Gliadel wafer, the current ... - Crain's Chicago Business,

Pituitary Tumors  May 31, 2005
...bischloroethyl-nitrosourea (BCNU, or carmustine). Implantation of the GLIADEL wafer serves two important purposes. First, the drug is ... - WOWT,

Guilford Pharmaceuticals Restarts AQUAVAN(R) Clinical Development ...  Apr 21, 2005
Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ... - Yahoo News

Heeding the call of biotech  Apr 21, 2005
Guilford has been struggling over the past few years, missing marketing opportunities for its Gliadel wafer, a brain cancer treatment, and dealing with ... - Baltimore Sun

Guilford expects profit in '08  Apr 6, 2005
Sales of Guilford's brain cancer drug, the Gliadel wafer, is also critical to its ability to reach profitability, Mitchell said. ... - Baltimore Business Journal

New strategies at Guilford  Apr 7, 2005
Instead, Guilford will build the company around its Gliadel wafer, which treats brain cancer, and Aquavan, a light sedative in its third phase of clinical ... - Baltimore Sun

Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data ...  Mar 8, 2005
Presently, Guilford markets two commercial products, GLIADEL® Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT ... - Yahoo News (press release)

Guilford takes wider loss as portfolio expands  Mar 2, 2005
Sales of Guilford's Gliadel wafer, used to treat brain cancer, rose 44 percent to $27.7 million from $8.5 million in 2003, which the company credits to the ... - Baltimore Business Journal,

No information provided.